Kamyar Firouzi, PhD

Dr. Kamyar (Kam) Firouzi’s work centers on developing next-generation neural interfaces that unite decoding, modeling, and modulation of brain activity. His research integrates focused ultrasound (FUS) neuromodulation, blood–brain-barrier (BBB) opening, and microchip-based sensing (CMUT/ASIC) with AI-driven neural decoding and generative modeling to build adaptive communication systems between the brain and machines. At Yale, he focuses on translating cutting-edge neurotechnology research into clinical and commercial applications, advancing experimental platforms into scalable systems for cognitive restoration, neurorehabilitation, and human–computer symbiosis.

Prior to Yale, Dr. Firouzi co-founded and led Althea, a pioneering agentic AI company that redefined human–computer interaction in healthcare. Althea developed proprietary multimodal language models and voice-based agentic systems that enable computers to reason, speak, and act, augmenting clinical teams and patient engagement. Through Althea, he demonstrated how agentic AI can serve as a powerful layer of human–AI interface, extending intelligence and decision support across complex healthcare systems. Earlier in his career, Dr. Firouzi co-founded Liminal Sciences, a neurotechnology company that introduced acousto-encephalography (AEG), the first noninvasive method for real-time monitoring of cerebral blood flow and pressure, later merged with Hyperfine (NASDAQ: HYPR).

Across his academic and entrepreneurial work, Dr. Firouzi continues to explore how neural decoding, AI architectures, and high-performance computing can be unified to advance precision neuromodulation, brain–AI interfaces, and the next era of intelligent human augmentation.